IDH1 and glioma: The inconsistency of IDH inhibitors’ preclinical data in gliomas may depend on the fact that most IDH1-mut glioma cell lines and xenografts are derived from grade III or grade IV tumors with acquired tertiary genetic alterations in the mitogenic signaling pathways.